348 results about "Serotype" patented technology

The invention belongs to the technical field of nano antibodies, and particularly relates to a nano antibody specifically bound with AAV9 and application of the nano antibody. The nano antibody provided by the invention can be specifically combined with the AAV9 adeno-associated virus without being combined with other AAV serotypes such as AAV2, AAV5 and AAV8, so that high-sensitivity and high-specificity detection of the AAV9 adeno-associated virus is realized. In practical application, the nano-antibody coupled solid-phase carrier provided by the invention is adopted as an affinity filler, the AAV9 adeno-associated virus can be effectively captured and mildly eluted, the virus purification and recovery effects are effectively improved, and the nano-antibody coupled solid-phase carrier is suitable for high-purity recovery of the AAV9 adeno-associated virus.

The invention provides a group of specific antibodies for detecting botulinum toxin A and application thereof, and belongs to the technical field of botulinum toxin detection. The invention provides a group of specific antibodies for detecting botulinum toxin A or antigen binding fragments thereof. The specific antibodies or the antigen binding fragments thereof comprise a rabbit monoclonal antibody 1F11 or an antigen binding fragment thereof and a rabbit monoclonal antibody 2A10 or an antigen binding fragment thereof. The time-resolved immunodetection kit prepared by the invention has good detection sensitivity, specificity, repeatability and sample matrix tolerance, the detection range is 0.02 ng / mL-10 ng / mL, the detection limit is 0.02 ng / mL, cross reaction with other serotype botulinum toxins (B, E and F) does not exist, and the time-resolved immunodetection kit is not influenced by sample matrixes such as ham sausages and thick broad-bean sauce. The detection system established by the invention has a good application prospect in detection of botulinum toxin type A.

The invention belongs to the field of veterinary biotechnology detection, and particularly relates to a hybridoma cell strain and a monoclonal antibody for detecting or identifying MDV-1 and application of the hybridoma cell strain and the monoclonal antibody. The hybridoma cell strain MDV-1Mab-pp38-E2 is obtained through screening by taking pp38 protein of MDV-1 as immunogen, the preservation number is CCTCC NO: C202501, the monoclonal antibody generated by the hybridoma cell strain can recognize I-type chicken Marek's disease virus strains with different serum, and the monoclonal antibody can be used for identifying the type I chicken Marek's disease virus strains with different serum types. The kit has good specificity and sensitivity and can be used for exogenous virus detection of the serum type I chicken Marek's disease virus in poultry virus live vaccines without cross reaction with serum type II chicken Marek's disease virus, serum type III chicken Marek's disease virus, chicken egg drop syndrome virus (EDSV) and other common poultry disease viruses, and the kit has good specificity and sensitivity and can be applied to exogenous virus detection of the serum type I chicken Marek's disease virus in poultry virus live vaccines. The kit can also be used for clinical identification, virus content determination and epidemiological investigation of serotype I chicken Marek's disease virus.

The invention relates to the technical field of molecular biology, in particular to an avian adenovirus serum type 4 colloidal gold test strip based on a monoclonal antibody and application of the test strip. According to the invention, two monoclonal antibodies (6B3 and 8G11) aiming at FAdV4 penton protein are successfully prepared through a hybridoma technology, and both the monoclonal antibodies show high titer and strong serotype specificity. Specific analysis proves that the two monoclonal antibodies can recognize 12 FAdV4 isolates from different sources, and do not have cross reaction with other FAdV serotypes or common poultry pathogens. According to the invention, through systematic optimization of key parameters, the detection sensitivity of the test strip is 7.81 * 10 < 4 > TCID50 / 0.1 mL, and the detection time is only 15 minutes. Clinical sample verification shows that compared with an ELISA method, the total coincidence rate is 98.6%.

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.

A bacteriophage for specifically lysing high-virulence capsular Klebsiella pneumoniae, pertaining to the field of microorganisms. The deposit number of the Klebsiella pneumoniae bacteriophage vB_kpnP_D39 is CCTCC NO: M 2024690. In the bacteriophage liquid formulation prepared on the basis of the bacteriophage, the working titer of the bacteriophage is greater than 1 × 109 PFU / mL. The bacteriophage has high specificity and can kill all high-virulence multidrug-resistant Klebsiella pneumoniae of K1, K2, and K57 capsular serotypes, with an adsorption efficiency of 99.60%. The bacteriophage exhibits a biofilm clearance rate of 47.4%-63.2% and a capsule clearance rate of 42.1%-60.6% against the high-virulence Klebsiella pneumoniae. The bacteriophage is expected to become a safe, non-toxic agent for the prevention, control, and treatment of high-virulence multidrug-resistant Klebsiella pneumoniae infections, or an antibiotic adjuvant.

The invention provides a characteristic protein of serotype I chicken Marek's disease virus and detection application, and belongs to the technical field of virus detection. The invention provides a recombinant gene derived from serum I type chicken Marek's disease virus. The nucleotide sequence of the recombinant gene is shown as SEQ ID No. 1. The recombinant gene disclosed by the invention is used for coding the MDV-1 recombinant PP38 protein, and the MDV-1 recombinant PP38 protein can be applied to enzyme-linked immuno sorbent assay (ELISA) detection. The invention also provides an ELISA detection kit constructed by using the MDV-1 recombinant PP38 protein, and the ELISA detection kit can be used for clinical MDV-1 serum antibody detection, SPF chicken screening, exogenous virus antibody detection of poultry live vaccines or virus seeds, epidemiological investigation and the like, so as to prevent and control transmission of MDV-1 infection.

The invention belongs to the technical field of nano antibodies, and particularly relates to a nano antibody specifically bound with AAV2 and application of the nano antibody. The nano antibody provided by the invention can be specifically combined with the AAV2 adeno-associated virus without being combined with other AAV serotypes such as AAV5, AAV8 and AAV9, so that high-sensitivity and high-specificity detection of the AAV2 adeno-associated virus is realized. In practical application, the nano antibody coupled solid-phase carrier provided by the invention is adopted as an affinity filler, the AAV2 adeno-associated virus can be effectively captured and mildly eluted, the virus purification and recovery effects are effectively improved, and the nano antibody coupled solid-phase carrier is suitable for high-purity recovery of the AAV2 adeno-associated virus.

The invention belongs to the technical field of antibody preparation, and particularly relates to a nano antibody for resisting different serotypes of adeno-associated viruses and application of the nano antibody. The nano antibody is selected from one of Nb1 to Nb24; the amino acid sequences of the heavy chain variable regions of the nano antibodies Nb1 to Nb24 are respectively shown as SEQ ID NO. 1 to 24. The nano antibody provided by the invention can sensitively and specifically bind to AAV, has excellent broad-spectrum recognition and binding capacity to various serotypes such as AAV2, AAV5, AAV8 and AAV9, and has a good application prospect in the fields of AAV immunodetection, affinity purification and the like.

The present disclosure relates to novel adeno-associated adenovirus (AAV) vectors comprising targeting peptides. More particularly, the present disclosure relates to an adeno-associated serotype 2 virus vector, AAV2, comprising a transgene encoding LIGHT wherein the viral capsid of the AAV2 vector comprises a targeting peptide that alters its tropism to target tumor endothelial cells; and a use of the carrier. The disclosure also relates to the use of said vectors in therapy, in particular in the treatment of cancer.

The invention relates to a new monoclonal antibody targeting the VP-1 protein of the capsid of the BK polyomavirus, fragments thereof, and uses of same for detecting infection with the BK polyomavirus. The monoclonal antibody is capable of recognizing at least all serotypes Ia, Ib2, II, III and IV of the VP-1 protein of the BK polyomavirus.

The antibody disclosed by the invention can specifically target high-virulence klebsiella pneumoniae of different serotypes, and specifically targets klebsiella pneumoniae of K1 and K2 serotypes. The antibody disclosed by the invention can be combined with high-toxicity klebsiella pneumoniae extracellular capsular polysaccharide with high affinity, has very strong neutralizing activity on klebsiella pneumoniae, and can mediate complement and mature neutrophil to neutralize and kill bacteria in an in-vitro killing experiment, so that the bacterial density is reduced, and the killing effect is improved. The traditional Chinese medicine composition can effectively prevent and treat high-toxicity klebsiella pneumoniae clinical infection and effectively improve pulmonary infection, provides a way for solving the problems of klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance in preventing, diagnosing and treating klebsiella pneumoniae infection, and has important value in development of a new generation of klebsiella pneumoniae medicine.

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.

The invention relates to the technical field of genetic engineering, in particular to Encapsulin fusion protein for expressing foot and mouth disease virus epitopes and application of the Encapsulin fusion protein in preparation of subunit vaccines. The invention discovers that different serotypes of foot-and-mouth disease virus antigen epitopes are inserted among the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids are replaced by the different serotypes of foot-and-mouth disease virus antigen epitopes; efficient and soluble expression of a target antigen in escherichia coli can be realized, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a broad-spectrum multivalent vaccine for foot-and-mouth disease.

A Fim3-producing BPZE1 derivative with sufficiently stable fim3 expression to provide improved protection in mice against Fim3-only producing clinical B. pertussis isolates was developed. The fim3 expression in BPZE1f3 did not alter the protective efficacy against Fim2+ strains, nor against strains that produce neither Fim2 nor Fim3.

The invention relates to a multi-target gene detection method based on a liquid phase chip, which comprises the following steps: S1, target genes: selecting O-type serum antigens to synthesize key genes; s2, probe design: synthesizing key genes aiming at seven serotype antigens, and designing a specific primer pair; s3, Luminex microsphere coding and coupling: using MagPlex microspheres with different fluorescence codes, and fixing a probe on the surface of the microspheres through a carboxyl-amino coupling method; s4, carrying out multiplex PCR amplification and hybridization detection; s5, a data analysis algorithm is adopted, and a threshold value is set, wherein a negative control MFI mean value + 3 * standard deviation is a Cuff value; and positive judgment: the MFI value of the microsphere corresponding to a certain serotype is greater than or equal to Cuff, and the signal-to-noise ratio (S / N) is greater than or equal to 5. By adopting the technical scheme, the method is based on a Luminex liquid phase chip technology, target gene sequences are amplified through multiple PCR (Polymerase Chain Reaction), and high-flux specific detection on seven serotypes of Escherichia coli is realized by combining microsphere coding probe hybridization and a biotin-streptavidin signal amplification system.

The invention provides a recombinant oncolytic virus for treating solid tumors with rare and rare gene mutations, which is an OAV treatment platform subjected to triple virus structural protein gene modification and triple adenovirus serotype chimerism, and is named as NeoViron. NeoViron can directly deliver tumor neoantigens to a plurality of solid tumors, especially tumors with rare mutations, and a new general strategy is provided for treating a plurality of intractable tumors.

The invention discloses mannheimia haemolytica outer membrane vesicles as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The OMV is separated from Mh-5 strain culture supernatant through tangential flow ultrafiltration combined with an ultracentrifugation technology, and animal experiments prove that a high-level IgG / IgM antibody can be induced by intramuscular injection of 50 micrograms per mouse, expression of inflammatory factors such as IL-6 and TNF-alpha of the spleen is remarkably improved, the protection rate after challenge reaches 85.7%, and pathological damage is remarkably lighter than that of an inactivated vaccine group. According to the scheme provided by the invention, the problems of insufficient serotype coverage and antibiotic resistance in the prior art are solved, and a new strategy is provided for prevention and control of mannheimia haemolytica.

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody 1E12 for specific detection of AAV6 and application of the monoclonal antibody 1E12. According to the monoclonal antibody 1E12 provided by the invention, a heavy chain variable region and a light chain variable region respectively comprise three complementary determining regions (CDR) corresponding to SEQ ID NO.1-3 and SEQ ID NO.4-6. The CDRs endow the antibody with high specificity and affinity to AAV6, the antibody can accurately recognize AAV6 virus without cross reaction with other serotypes, and the detection sensitivity reaches 4 * 10 < 6 > vg / ml level. The antibody is suitable for development of multiple detection tools such as a double-antibody sandwich ELISA kit, a test strip and an antibody chip, especially has excellent performance in a biotin-avidin amplification system, can be used for virus identification, titer determination and clinical dose evaluation of AAV6, and provides an effective means for standardized and high-throughput detection.

The present invention pertains to a vaccine comprising in combination an IgM protease antigen of Streptococcus suis and a Streptococcus suis bacterin of serotype (9), sequence type (16), for use in a method for protecting pigs against a pathogenic infection with Streptococcus suis serotype (9), sequence type (16).

The invention discloses a pasteurella phage PTP1APTYT15 as well as a composition, a kit and application of the pasteurella phage PTP1APTYT15, the pasteurella phage PTP1APTYT15 is preserved in Guangdong Microbial Culture Collection Center on September 10, 2025, the preservation number of the pasteurella phage PTP1APTYT15 is GDMCC NO: 66946-B1, and the pasteurella phage PTP1APTYT15 is classified and named as Pasteurella phage PTP1APTYT15. The pasteurella phage PTP1APTYT15 provided by the invention has the characteristics of high temperature resistance and alkali resistance, and can be used for cracking pasteurella of various serotypes. In addition, the bacteriophage is high in proliferation efficiency and high in splitting capacity, has no adverse effect on human or animal health, and has good biological safety.

The invention discloses a preparation method of a boiling antigen for vibrio parahaemolyticus serum agglutination. The preparation method comprises the following steps: selecting common serotype vibrio parahaemolyticus in monitoring for resuscitation; scraping a ring of placenta by using 10 mu L of an inoculating loop, dissolving the placenta in 1 mL of normal saline to prepare a bacterial suspension, and preparing 3 tubes of bacterial suspensions from each strain; boiling the bacterial suspension in boiling water for 1 hour, 45 minutes and 30 minutes respectively; and after boiling, centrifuging at 10000 rpm for 10 minutes, discarding the supernate, and reserving the precipitate as a boiling antigen for serum agglutination. The result shows that the agglutination accuracy after boiling for 1 hour is 100%, and the agglutination degree is 2 + or above; and no significant difference exists between 45 minutes of boiling and 1 hour of boiling, and no significant difference exists between 30 minutes of boiling. Compared with a high-pressure method, the method has the advantages that the operation time is shortened by 2-3 hours, special equipment certificates are not needed, and the method is suitable for daily detection and food poisoning traceability.

The present invention relates to primer sets for the diagnosis of foot-and-mouth disease and to a method for the diagnosis of foot and mouth disease using said primer sets by the Loop Mediated Isothermal Amplification (RT-LAMP) method. With the primers of the present invention and the diagnostic method using these primers, A, O and Asia 1 serotypes of foot and mouth virus can be diagnosed quickly and with high sensitivity.

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

The present disclosure generally relates to a method for rapidly detecting the presence or absence of serotypes that cause lymphogranuloma venereum (LGV) of Chlamydia trachomatis in biological or non-biological samples. The method may include performing an amplification step, a hybridization step, and a detection step. Further provided are oligonucleotide primers and probes targeting the pmpH gene of the L serotype of Chlamydia trachomatis, as well as a kit designed to detect the L serotype.

This invention belongs to the field of molecular biology detection technology, specifically relating to a primer and probe combination for detecting avian Salmonella based on the RAA-LFD method and its application, particularly to a primer and probe combination for detecting three avian serotypes of Salmonella: Salmonella pullorum, Salmonella enteritidis, and Salmonella typhimurium, based on the RAA-LFD method and its application. This invention designs different types of probes and primers targeting the genes of serotypes SP, SE, and STM of Salmonella. Using the primer and probe combination of this invention, rapid, sensitive, and specific detection of Salmonella serotypes and the three avian Salmonella serotypes SP, SE, and STM can be achieved, greatly shortening the detection cycle of avian salmonellosis and improving the detection efficiency and accuracy of avian salmonellosis.

The invention discloses a porcine circovirus type 2 and haemophilus parasuis bivalent inactivated vaccine and a preparation method thereof. According to the invention, a porcine circovirus strain, a haemophilus parasuis serum type 4 strain and a haemophilus parasuis serum type 5 strain which are epidemic in situ are respectively separated and obtained, and the microbial preservation numbers of the porcine circovirus strain, the haemophilus parasuis serum type 4 strain and the haemophilus parasuis serum type 5 strain are respectively CGMCC (China General Microbiological Culture Collection Center) No.47094, CGMCC No.46698 and The separated strain or bacterial strain is prepared into a bivalent inactivated vaccine, and lentinan is added in the vaccine preparation process to enhance the immune effect; a safety evaluation result shows that local or whole-body adverse reaction caused by the bivalent vaccine does not occur, so that the safety of the bivalent vaccine is good; the immune efficacy evaluation result of the bivalent vaccine shows that the bivalent vaccine can provide complete protection for animals aiming at the in-situ epidemic porcine circovirus, haemophilus parasuis serotype 4 and haemophilus parasuis serotype 5, and has good immune protection efficacy.

The disclosure discloses a chemical synthesis method and an application of V. cholerae serotype O100 O-antigen oligosaccharides, belonging to the field of chemical technologies. The disclosure uses three monosaccharide building blocks and five carboxylic acid derivatives to synthesize five oligosaccharide fragments of V. cholerae serotype O100 O-antigen under the action of the solvent effect, temperature effect, neighboring group participation effect, etc., through orthogonal protection, selective assembly and amide coupling. The absolute configurations and immunological effects of 3,5-dihydroxyhexanoyl in the O-antigen trisaccharide are illustrated by the synthesized oligosaccharide fragments in combination with the NMR analysis and glycan microarray technology, thereby providing a theoretical basis for further structure-activity study and minimal antigenic epitope screening. The disclosure has excellent application prospects in the aspects of development of V. cholerae synthetic glycoconjugate vaccines and new drugs, etc.

This invention discloses a method for preparing a bivalent inactivated vaccine against bovine Pasteurella multocida type A and B and hemolytic Mansicular disease, belonging to the field of vaccine technology. The invention involves isolating capsular serum Pasteurella multocida type A, Pasteurella multocida type B, and hemolytic Mansicular disease; separately expanding the culture of these bacteria, then inactivating and concentrating the bacterial suspensions, and resuspending them in PBS to prepare bacterial suspensions; and finally, mixing the Pasteurella multocida type A, Pasteurella multocida type B, and hemolytic Mansicular disease suspensions with aluminum hydroxide adjuvant to prepare the inactivated vaccine. This invention provides simultaneous prevention of two diseases—bovine fibrinous purulent pneumonia and bovine hemorrhagic septicemia—as well as bovine Mansicular disease through vaccine immunization. The vaccine demonstrates good safety, stable immunization efficacy, and a long duration of immunity.